| 货号 | MAB2774-SP |
| 别名 | CMRF35-like molecule 1; CD300 molecule-like family member f; CD300f; CD300LF; CLIM1; CLM1; CLM-1; DIgR2; IGSF13; IREM1; IREM-1; LMIR3; NKIR; Pigr3 | 全称 | Leukocyte Mono Ig-like Receptor 3 |
| 反应种属 | Human |
| 应用 | Flow Cytometry(0.25 µg/106cells) Immunocytochemistry(8-25 µg/mL) |
| 目标/特异性 | Detects human CD300f/LMIR3 in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human LMIR1, 2, 4, 5, 6, or recombinant mouse LMIR3 is observed. |
| 使用方法 | Flow Cytometry: 0.25 µg/106cells Immunocytochemistry: 8-25 µg/mL |
| 来源 | Reconstitute at 0.5 mg/mL in sterile PBS. |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 146722 (Human); 246746 (Mouse) |
| 应用文献 | |
| R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. Sphingomyelin and ceramide are physiological ligands for human LMIR3/CD300f, inhibiting FcepsilonRI-mediated mast cell activation. | |
| 纯化方式 | Protein A or G purified from hybridoma culture supernatant |
| 免疫原 | Y3 rat myeloid cell line transfected with human CD300f/LMIR3 |
| 生物活性 | Human |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.5 mg/mL in sterile PBS. |
| 背景 | CD300f, also known as CD300LF, LMIR3, IREM-1, CLM-1, IgSF13, DIgR1, and MAIR-V, is a 50‑60 kDa glycoprotein member of the immunoglobulin superfamily (1). Human CD300f consists of a 137 amino acid (aa) extracellular domain (ECD) with one Ig-like V-type domain, a 21 aa transmembrane segment, and a 113 aa cytoplasmic domain that contains multiple immunoreceptor tyrosine-based inhibitory motifs (ITIMs) or ITIM-like sequences (2, 3). Alternate splicing generates additional isoforms that carry substituted C-terminal tails of varying lengths and sequences following the ECD or transmembrane segment (3). Within the ECD, human CD300f shares 43% aa sequence identity with mouse and rat CD300f. CD300f is expressed on the surface of dendritic cells, monocytes, granulocytes, and mast cells as well as on acute myeloid leukemia (AML) blasts (2‑4). Pervanadate treatment or antibody crosslinking of CD300f induces phosphorylation of tyrosine residues in the cytoplasmic domain and the subsequent recruitment of phosphatases SHIP, SHP-1, SHP-2, and the p85 alpha subunit of PI3K (2, 3, 5, 6). CD300f ligation can induce cell death and inhibit signaling through multiple receptors including Fc epsilon RI, LMIR4, SCF R, TLR2, TLR3, and TLR9 (3‑8). In contrast, it enhances TLR4-mediated signaling/cytokine production in mast cells through association with the activating signaling protein FcR gamma (5). In mouse, a splice variant of CD300f (known as DIgR2, with a 7 aa insertion in the ECD) inhibits CD4+ T cell activation and in vivo Th1 and CTL responses (9). CD300f is upregulated on monocytes surrounding experimentally-induced spinal cord demyelination and functions as a negative regulator of inflammation in the CNS (10). |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 参考文献 |
|
CD300f/LMIR3 in Human PBMCs. CD300f/LMIR3 was detected in immersion fixed human peripheral blood mononuclear cells (PBMCs) using Rat Anti-Human CD300f/LMIR3 Monoclonal Antibody (Catalog # MAB2774) at 15 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Rat IgG Secondary Antibody (red; Catalog # NL013) and counterstained with DAPI (blue). Specific staining was localized to cell surfaces. View our protocol for Fluorescent ICC Staining of Non-adherent Cells. |
